Work Experience:
Intramed Pty. Ltd. (now known as Bodene / Fresenius)
Period: 1994-1997
Post: Sales assistant

Job Description: Sales, Management Statistics, Production Forecasts for Large Volume Parental (LVP's), customer relations with all products.

St Georges Hospital Pharmacy
Period: 1997-2001
Post: Pharmacist Assistant Trainee
Job Description:
Day to day running of the Oncology pharmacy, stock control, assisting the pharmacist, mixing chemotherapy and dispensing scripts, liaising with pharmaceutical representatives, processing of invoices, compilation of monthly reports and replenishing stock.

GVI Oncology, Eastern Cape
Period: August 2001 to April 2003
Post: Clinical Research Co-ordinator
Job Description:
Consenting patients, Completing Serious adverse event reports, Finance of trials, liaising with sponsors and patients including their families and general practitioners, Completing Case Report forms, IVRS, following protocols, general administration work, traveling for Investigator meetings, drawing up of Standard Operating Procedures, assisting patients with their medical aids, drug accountability, etc.

Johannesburg Oncology, University of the Witwatersrand
Period: May 2003 to July 2006
Post: Clinical Research Co-ordinator
Job description:
Consenting patients, Completing Serious adverse event reports, Finance of trials, liaising with sponsors and patients including their families and general practitioners, Completing Case Report forms, following protocols, general administration work, assisting patients with their medical aids, implementing systems for the smooth running of the site, etc, Basically all aspects of Clinical Trials as well as training junior co-ordinators and hiring auxiliary staff,

RDDA, South Africa (CRO)
Period: July 2006 to June 2009
Post: Clinical Research Associate

Novartis
Period: July 2009 to May 2012
Post: Clinical Research Associate

Pharm-olam International
Period: May 2012 to 2013
Post: Senior Clinical Research Associate

INC Research
Period: 2013 to 2014
Post: Senior Clinical Research Associate

Clintec International
Period: 2015 to 2016
Post: Senior Clinical Research Associate

BioCollections Worldwide
Period: 2011 to March 2016 (Contract)
Post: Senior Clinical Research Associate
Period: April 2016 to present
Post: South African Director & Country Manager

Clinical Trial Experience:
PARTICIPATION IN CLINICAL TRIALS (INTERNATIONAL)

2001 to 2003
Co-Ordinator for:
Phase III Metastatic Colon Ca (started 2002 and ongoing CPT-GMA-301)
Phase III NSCLC (started 2001 and ongoing 104864/387)
Phase II trials in Non Small Cell Lung Cancer (2000 and 2001) (Iressa ZD1839IL0014&16)
Metastatic Ca Colon (ended in April2001-CPT CMA 204)
Pain Control (2000 and 2001 – MSO/95008/008).
Metastatic Melanoma (ongoing – L00070 IN 204 S1)
Ca Stomach (started 2000 - 2002 CPT-V-306)
Small Cell Lung Cancer (started August 2001-2002 104864/389)
Metastatic Breast Cancer (started July 2001and ongoing L00070 207 BO).
Adjuvant Breast Ca (started Sept 2001 and ongoing BCIRG 005 and 006)
Adjuvant Colon Ca (2000-2002 CPT-V-307
Phase II Ca Pancreas (started 2000 – 2002 R115777-INT-16)
Phase II Ca Pancreas (started 2002-2002 PC4)

2003 to 2006
BREAST CANCER
B3T-MC-JTAJ
Randomised, Placebo controlled, double blind phase II study of Docetaxel compared to Docetaxel plus LY335979 in women with metastatic or locally recurrent Breast Cancer who have received one prior chemotherapy regimen.
L000701IN206BO
2nd line
Cardio protection with Cardioxane in advanced/metastatic Breast Cancer.
EGF 30001
Lapatinib plus Paclitaxel in Metastatic Breast Cancer.
EGF 30008
Lapatinib and Letrazole versus Letrazole.
YMB1002/02
DPPE combined with Epirubicin and Cyclophosphamide in metastatic/recurrent Breast Cancer.
9238IL/0048
Fulvestrant vs Exemestane in post menopausal women with hormone receptor positive advanced Breast Cancer.
CFEM345D2406 - EZOFAST
Zoledronic Acid in the prevention of cancer treatment related bone loss in post menopausal women with Cancer.

Docetaxel monotherapy or Docetaxel and Doxil® for the treatment of adv. breast cancer.
(Janssen Cilag)
Femara plus Herceptin in Post-menopausal metastatic Breast Cancer.
Oral Vinorelbine vs IV Vinorelbine with metastatic Breast Cancer
Taxotere survey (phase 4)

NON SMALL CELL LUNG CANCER
ZD644/CARBO TREATMENT
A randomised, partially blinded, phase II study to assess the safety, tolerability and efficacy of ZD6474 alone or in combination with Paclitaxel and Carboplatin in subjects with previously untreated locally advanced or metastatic non small cell lung cancer.

Phase III trial of Pivanex plus Docetaxel in relapsed non small cell lung cancer.
ZD6474/0003
Phase III trial of ZD6474 vs Gefitinib in relapsed non small cell lung cancer
1839IL/0710
Disease-related symptoms comparing ZD1839 (Iressa™) plus best supportive care (BSC) versus Placebo plus BSC in symptomatic patients with advanced NSCLC.
PM0259 CA 301 JI
(Alternating IV and oral) Vinorelbine plus Cisplatin versus Docetaxel plus Cisplatin locally advanced or metastatic non small cell lung cancer.
Newly diagnosed lung patients

COLORECTAL CANCER
Study of the efficacy of Xaliproden in reducing the neurotoxicity of the Oxaliplatin and 5FU/LV combination in patients with metastatic colorectal carcinoma.
V307
Adjuvant treatment of stage III colon cancer.

A multicentre observational study of Campto (Irinotecan) in the treatment of subjects with advanced colorectal cancer in South Africa.

HEPATOCELLULAR CARCINOMA:
(Eximias)Survival of patients with unresectable hepatocellular carcinoma treated with Thymitaq to patients treated with Doxorubicin. Patients with unresectable and/or metastatic HCC (Child Pugh A) who have received only prior local anti cancer treatment.

(Wyeth) Interferon Alfa alone, CCI-779 alone, and the combination of Interferon Alfa and CCI-779 in subjects with advanced Renal Cancer.

LEUKAEMIA
STI571/GLEEVEC
Chronic Phase 0113
Blast Crisis 0115
Dasatinib, CA180-013, 017, 034, 035
400mg Gleevec vs 800mg in newly diagnosed patients.

LYMPHOMA:
EORTC
Chimeric Anti CD20 monoclonal antibody in remission induction and maintenance treatment of relapsed follicular Non Hodgkin's Lymphoma.

NASOPHARYNGEAL CARCINOMA / HEAD & NECK:
TAX-ZA-603
Cisplatin and Docetaxel (Taxotere) plus radiation therapy in radiotherapy and chemotherapy naive patients.
Iressa vs Methotrexate in previously untreated patients with Squamous cell Carcinoma of the Head and Neck.

GIST
Imatinib in gastrointestinal stromal tumors.

OVARIAN
Patupilone vs Doxil in patients with recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer.

CLINICAL TRIALS AS A CRA 2006 TO 2009:
Overactive Bladder Syndrome
Metastatic Breast Cancer x 2 (Pharmolam YMB1002-02 included)
Pediatric Neurology x 2 studies
Cancer Pain
HIV

CLINICAL TRIALS SINCE JULY 2009 to May 2012
Metastatic Breast
Adjuvant Breast
1st Line Lung Cancer
Adjuvant Gastro Intestinal Stromal Tumours
Myelofibrosis

CLINICAL TRIALS FROM MAY 2012 TO PRESENT
Prevention of Chemo induced nausea and vomiting in subjects receiving Moderately Emetogenic Chemo
Prevention of Chemo induced nausea and vomiting in subjects receiving Highly Emetogenic Chemo
Hemophilia
Metastatic Breast
HIV; HBV and HCV
Cardiovascular Study
Pediatric Oncology (Hemophilia)

Responsibilities summarised below:

X Feasibilities
X Query Resolution
X Attendance to Investigator Meetings
X Drug Accountability / Return
X Delivery of GCP Training / General Training
X Management of SAE's
X Submissions to MCC/Ethics
X Audits
X Site Selection Visits
X Re-Labeling process

X Initiation Visits
X Revising SOP's
X Monitoring and SDV
X Monthly Pass through Inv to Sponsors
X Site Closure visits
X Training CTA & Receptionist/Filing Clerk
X Development of new sites / Investigators
X General other research related requirements

Accredited with American Clinical Research Professionals 2010 & 2020. Accreditation Current.